Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung Cancer (aNSCLC). A partitioned survival model was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical, safety and utility data were extracted from literature. Direct medical costs reflecting the year 2023 were included in the analysis (€). Model outcomes were patients’ life years (LYs), quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs). Total cost per patient with lorlatinib, alectinib, crizotinib, and brigatinib was estimated to be €188,205, €183,343, €75,028, and €145,454 respectively. Lorlatinib appeared to yield more LYs and QALYs gained versus alectinib, crizotinib, and brigatinib. Hence, lorlatinib resulted in ICERs of €4,315 per LY gained and €4,422 per QALY gained compared to alectinib, €34,032 per LY gained and €48,256 per QALY gained versus crizotinib and €16,587 per LY gained and €26,271 per QALY gained compared to brigatinib. Lorlatinib provides substantial clinical benefit and appears to be a cost – effective treatment option compared to 1st and 2nd generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.</p

Additional file 2: of Economic evaluation of trimetazidine in the management of chronic stable angina in Greece

Drug acquisition cost. Data description: Proportion of patients using each therapy, mean drug daily dose and relative drug acquisition cost is presented in the file. (DOCX 70 kb

Additional file 1: of Economic evaluation of trimetazidine in the management of chronic stable angina in Greece

Questionnaire. Data description: The questionnaire used to collect data from local Key Opinion Leaders is presented in the file. (DOCX 65 kb

Additional file 1: Table S1. of Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

Drug acquisition cost considered in the model. (DOCX 79 kb